Kempen

Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a unique class of therapeutic proteins derived from single-domain antibody fragments. These innovative proteins are designed to address a variety of serious human diseases, including inflammation, hematology, oncology, and pulmonary conditions. Currently, Ablynx has around 25 projects in its pipeline, with five Nanobodies in clinical development. By combining the advantages of traditional antibodies and small chemical molecules, Ablynx aims to provide new therapeutic options that can significantly improve patient care and outcomes.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.